MISSISSAUGA, ON, May 5, 2014 /CNW/ - Cipher Pharmaceuticals Inc.
(TSX: DND) ("the Company"), in accordance with Toronto Stock
Exchange requirements, announced the voting results from
its Annual General Meeting of Shareholders held May 2, 2014 in Toronto,
Ontario.
A total of 14,793,915 million common shares
representing 59.16% of the Company's issued and outstanding common
shares were voted in connection with the meeting. Shareholders
voted in favour of all items of business put forth, including the
appointment of PricewaterhouseCoopers Canada as the auditor of the
Company and the election of all director nominees were as
follows:
| Motions |
% of Shares Voted For |
% of Shares Voted
Withhold |
| Elect Gerald P. McDole |
99.92% |
0.08% |
| Elect Dr. John D. Mull |
99.88% |
0.12% |
| Elect Stephen R. Wiseman |
99.92% |
0.08% |
| Elect Dr. Stefan Aigner |
99.92% |
0.08% |
| Elect Dr. William D. Claypool |
99.92% |
0.08% |
| Elect Thomas G. Wellner |
99.92% |
0.08% |
| Appointment of Auditors |
99.99% |
0.01% |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: DND) is a growing specialty
pharmaceutical company with three commercial products and a fourth
in development. Our product candidates are typically improved
formulations of successful, currently marketed drugs. We in-license
a product, manage the required clinical development and regulatory
approval process, and either out-license it to a marketing partner,
or, in Canada, we may market
the product ourselves. Our core capabilities are in clinical and
regulatory affairs, product licensing, supply chain management, and
marketing and sales. Since the Company was founded in 2000, we have
achieved final regulatory approval in the U.S.
and Canada for all three
of our original products and completed six marketing partnerships,
generating growing licensing revenue.
SOURCE Cipher Pharmaceuticals Inc.